1. Home
  2. CISO vs CMMB Comparison

CISO vs CMMB Comparison

Compare CISO & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CISO Global Inc.

CISO

CISO Global Inc.

HOLD

Current Price

$0.26

Market Cap

13.2M

Sector

Technology

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$1.57

Market Cap

11.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CISO
CMMB
Founded
2015
2004
Country
United States
Israel
Employees
N/A
12
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
11.1M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
CISO
CMMB
Price
$0.26
$1.57
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
443.0K
217.7K
Earning Date
05-15-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
79.31
101.67
EPS
N/A
0.04
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$38.00
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$0.87
52 Week High
$1.48
$3.86

Technical Indicators

Market Signals
Indicator
CISO
CMMB
Relative Strength Index (RSI) 42.78 44.08
Support Level $0.22 $1.51
Resistance Level $0.32 $1.83
Average True Range (ATR) 0.02 0.27
MACD -0.00 -0.05
Stochastic Oscillator 18.94 4.85

Price Performance

Historical Comparison
CISO
CMMB

About CISO CISO Global Inc.

CISO Global Inc provides cybersecurity compliance and is a software firm composed of trained and seasoned security professionals. The services are used to protect clients' data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in the U.S., Chile, and all other countries. The maximum revenue is generated from the U.S. The products and services include: security managed services, professional services, and cybersecurity software.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: